Results 11 to 20 of about 2,804,111 (259)
Fremanezumab for the Preventive Treatment of Chronic Migraine. [PDF]
New England Journal of Medicine, 2017 BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine.
Aycardi, Ernesto +9 more
core +3 more sources
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
European Journal of Medical Research, 2022 Background Resistant chronic migraine is a highly disabling condition which is very difficult to treat. The majority of the treatments for migraine prophylaxis are nonspecific and present weak safety profiles, leading to low adherence and discontinuation.
Hugo Sevivas, Paula Fresco
doaj +2 more sources
The Journal of Headache and Pain, 2021 Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data from 3 randomized clinical trials
Michael Ament +6 more
doaj +2 more sources
Current and emerging evidence-based treatment options in chronic migraine: a narrative review
The Journal of Headache and Pain, 2019 Background Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological ...
Elio Clemente Agostoni +15 more
doaj +2 more sources
The Journal of Headache and Pain, 2022 Background Chronic migraine places a disabling burden on patients, which is extensively modeled by the nitroglycerin (NTG)-treated animal model. Although the NF-κB pathway is involved in an increase in CGRP levels and activation of the trigeminal system ...
Hao Chen +7 more
semanticscholar +1 more source
CNS Drugs, 2022 Criteria, including clinical features and effective outcomes, for access and persistence of novel but costly treatments may vary between countries, thus affecting the health of patients.
L. Iannone +5 more
semanticscholar +1 more source
Management of chronic migraine
British medical journal, 2022 Chronic migraine is a neurologic disorder associated with considerable disability, lost productivity, and a profound economic burden worldwide. The past five years have seen a dramatic expansion in new treatments for this often challenging condition ...
A. Hovaguimian, Julie Roth
semanticscholar +1 more source
The Journal of Headache and Pain, 2022 Background Clinical trials have shown that erenumab is effective and well-tolerated for the preventive treatment of chronic migraine. To extend the results from clinical trials, we assessed the real-world efficacy and safety of erenumab in patients with ...
C. K. Cullum +10 more
semanticscholar +1 more source
The Journal of Headache and Pain, 2022 Background and aims Chronic migraine is a common neurovascular brain disorder with substantial economic costs. We performed a systematic review to identify economic evaluations of pharmacological treatments for adults with chronic migraine.
S. Khanal +6 more
semanticscholar +1 more source
Toxins, 2022 OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a ...
D. Scuteri +7 more
semanticscholar +1 more source